SEC Form 4 · accession 0001567619-18-001755
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Lane
Officer — Corporate Vice President
Period of report
Aug 21, 2018
Accepted (ET)
Aug 23, 2018 · 6:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 21, 2018 | M | 2,112 | $62.00 | A | 5,519 | D | |
| Common Stock | Aug 21, 2018 | M | 2,226 | $79.54 | A | 7,745 | D | |
| Common Stock | Aug 21, 2018 | M | 1,500 | $67.85 | A | 9,245 | D | |
| Common StockF2 | Aug 21, 2018 | S | 5,838 | $243.7776 | D | 3,407 | D | |
| Common Stock | Aug 21, 2018 | S | 74 | $243.75 | D | 3,333 | D | |
| Common StockF3 | holding | — | — | — | 592 | I | by spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)F7,F4 | $62.00 | Aug 21, 2018 | M | 2,112 | D | — | Feb 13, 2024 | Common Stock | 2,112 | 0 | D |
| Non-Qualified Stock Option (right-to-buy)F7,F5 | $79.54 | Aug 21, 2018 | M | 2,226 | D | — | Feb 13, 2025 | Common Stock | 2,226 | 136 | D |
| Non-Qualified Stock Option (right-to-buy)F7,F6 | $67.85 | Aug 21, 2018 | M | 1,500 | D | — | Feb 13, 2026 | Common Stock | 1,500 | 9,249 | D |
Explanation of responses
- F1Includes 598 shares held in the reporting person's IRA account and 23 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2018.
- F2Represents the weighted average sales price of the shares sold ranging from a low of $243.75 to a high of $244.15 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein.
- F4Grant of option to buy 1,056 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F5Grant of option to buy 1,181 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2016, without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F6Grant of option to buy 10,749 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2017.
- F7Not applicable.